Sinovac Biotech Ltd. reported that its revenues in Q2 rose 73% to $16.5 million. The increase was partly due to a $4.6 million government order for the company’s vaccines following the May 2008 Sichuan earthquake. Without the government order, Sinovac’s revenues would have been higher by only 25%. Sinovac’s main revenue driver is Healive®, a vaccine for hepatitis A. The company’s Q2 net income of $3.3 million almost equaled its 2007 first half (six months) profit of $3.5 million. More details...

Stock Symbol: (AMEX: SVA)